Anil Koul
Indian scientist (born 1972) / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Anil Koul?
Summarize this article for a 10 year old
Anil Koul (born 1 June 1972) is a scientist and former Director of the CSIR-Institute of Microbial Technology (IMTECH),[1] a premier biomedical and biotechnology research institution under Council of Scientific and Industrial Research (CSIR) under Ministry of Science and Technology, Govt. of India.
This article's lead section may be too long. (January 2021) |
Anil is currently a member of scientific advisory board of CSIR, a high powered committee for scientific management of CSIR organization, chaired by principal scientific adviser to the Prime Minister, Prof. Vijay Raghavan.
Anil has more than 18 years of pharmaceutical R&D expertise and currently is vice president and Head of Global Public Health discovery at Johnson & Johnson (J&J). He is member of Board of Directors of Janssen Pharmaceutica NV, the European subsidiary of J&J.
Additionally, Anil was recently appointed as Professor of Translational Discovery at London School of Hygiene and Tropical Medicine (LSHTM), where he will set up a laboratory of Translational drug discovery.[2]
Anil's major scientific career achievement is his key role in discovery and development of new tuberculosis drug Bedaquiline - the first drug to be approved in the last 45 years for treatment of drug-resistant tuberculosis.